40 participants
Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-07-14
- Start Date:
- 2023-02-15
- Completion:
- 2026-12-31
Conditions
- Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Interventions
- DRUG
No Results Yet